Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function
Спектр глазных проявлений болезни Баттена, ассоциированной с CLN2 (болезни Янского—Бильшовского), коррелирует с увеличением возраста и ухудшением неврологической функции
2013-08-28
SCID: 54.1/6efwx8dg
Discuss with AI
CLN2-associated Batten diseaseLINCL Ophthalmic Scalelate infantile neuronal ceroid lipofuscinosisophthalmic manifestationsoptical coherence tomography
Figures from the paper
Abstract (AI)
BACKGROUND: Late infantile neuronal ceroid lipofuscinosis (LINCL), one form of Batten's disease is a progressive neurodegenerative disorder resulting from a CLN2 gene mutation. The spectrum of ophthalmic manifestations of LINCL and the relationship with neurological function has not been previously described. METHODS: Patients underwent ophthalmic evaluations, including anterior segment and dilated exams, optical coherence tomography, fluorescein and indocyanine green angiography. Patients were also assessed with the LINCL Neurological Severity Scale. Ophthalmic findings were categorized into one of five severity scores, and the association of the extent of ocular disease with neurological function was assessed. RESULTS: Fifty eyes of 25 patients were included. The mean age at the time of exam was 4.9 years (range 2.5 to 8.1). The mean ophthalmic severity score was 2.6 (range 1 to 5). The mean neurological severity score was 6.1 (range 2 to 11). Significantly more severe ophthalmic manifestations were observed among older patients (p<0.005) and patients with more severe neurological findings (p<0.03). A direct correlation was found between the Ophthalmic Severity Scale and the Weill Cornell Neurological Scale (p<0.002). A direct association was also found between age and the ophthalmic manifestations (p<0.0002), with older children having more severe ophthalmic manifestations. CONCLUSIONS: Ophthalmic manifestations of LINCL correlate closely with the degree of neurological function and the age of the patient. The newly established LINCL Ophthalmic Scale may serve as an objective marker of LINCL severity and disease progression, and may be valuable in the evaluation of novel therapeutic strategies for LINCL, including gene therapy.
Key Findings
1
A cohort of 25 patients with CLN2-associated late-infantile neuronal ceroid lipofuscinosis underwent comprehensive ophthalmic and neurological assessment.
2
More severe ocular findings were significantly associated with worse neurological function (p<0.03), with a direct correlation between ophthalmic and Weill Cornell neurological severity scales (p<0.002).
3
Ophthalmic severity increased significantly with patient age, with older children showing more advanced ocular manifestations (p<0.0002).
4
The newly established LINCL Ophthalmic Scale may provide an objective marker of disease severity and progression for evaluating potential therapies, including gene therapy.
Research Object
Patients with CLN2-associated late-infantile neuronal ceroid lipofuscinosis (LINCL; Batten disease) and its ophthalmic manifestations
Research Subject
The spectrum and severity of ophthalmic manifestations and their correlations with patient age and neurological function
Publication Details
Publication Date
2013-08-28
Journal
Publisher
ISSN
Cited by
54
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by13
Management Strategies for CLN2 Disease2017
Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis2016
Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients2021
Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials2022
Brain Region–Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)2016
Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease2020
An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy2021
Clinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group2023
First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy2023
Enzyme Replacement Therapy in CLN2-Associated Retinopathy2025
Guidelines on the Diagnosis, Clinical Assessments, Treatment and Management for CLN2 Disease Patients2020
OCT Biomarkers in Ocular CLN2 Disease in Patients Treated With Intraventricular Enzyme Replacement Therapy2024
Visual perception and macular integrity in non-classical CLN2 disease2022